Instalab

Minimum FFRCT - LCX Test

Your most precise read on whether a narrowing in a key heart artery is actually starving your heart of blood.

Should you take a Minimum FFRCT - LCX test?

This test is most useful if any of these apply to you.

Told You Have a Borderline Narrowing
If a CT or angiogram showed a moderate narrowing, this can clarify whether it is actually limiting blood flow to your heart.
Having Chest Pain With Stable Symptoms
If you have ongoing or recurrent chest discomfort, this can pinpoint whether a specific artery is the source before invasive testing.
Living With a Heart Transplant
If you have had a heart transplant, serial readings can catch diffuse vessel disease that focal stenosis measurements miss.
Sorting Out Conflicting Test Results
If your scans and stress tests disagree, this adds a functional read that often resolves the question without going to the catheterization lab.

About Minimum FFRCT - LCX

You can have a narrowing in a coronary artery that looks worrying on a scan and yet causes no real flow problem. You can also have a narrowing that looks modest on imaging but is genuinely choking off blood to your heart muscle. Anatomy alone cannot tell you which one you have.

Minimum FFRCT in the LCX (left circumflex artery) is a number, derived from a computer model of your coronary CT scan, that estimates how much pressure and flow drop across the most narrowed point in that specific artery. It tells you whether your left circumflex is functionally fine or whether a lesion there is actually limiting blood supply to part of your heart.

What This Number Actually Represents

FFRCT (fractional flow reserve from CT) is a dimensionless ratio between 0 and 1. It is not a molecule, hormone, or lab value drawn from blood. It is a calculation that takes the 3D image of your coronary arteries and uses fluid-dynamics or machine-learning software to estimate the pressure ratio across a narrowing under simulated maximum blood flow.

The "minimum" value in the LCX is the lowest point along that artery, usually just past the most significant narrowing. A value close to 1.0 means flow through the artery is essentially unrestricted. A lower value means a narrowing is causing a real pressure drop, which is how doctors define myocardial ischemia (blood flow that is not keeping up with what the heart muscle needs).

Why It Matters for Heart Disease

A standard coronary CT angiogram (CCTA) can tell you that an artery has a narrowing, but it cannot tell you whether that narrowing is actually limiting flow. This matters because not every narrowing needs a stent or surgery, and some narrowings that look mild are causing more trouble than they appear to. Adding FFRCT to the picture changes decisions.

In a registry of over 5,000 patients, adding FFRCT to coronary CT angiography reshaped management plans, cut down on unnecessary invasive catheterizations, and was linked to lower rates of major adverse cardiovascular events. In a randomized Chinese trial of 5,297 people with stable coronary disease, adding CT-FFR to routine CCTA lowered the rate of invasive coronary angiography within 90 days while keeping one-year heart event rates similar to standard care.

How a Lower Number Predicts Risk

Lower minimum FFRCT values track with higher risk of bad heart outcomes, and the relationship is a sliding scale, not a hard cliff. A meta-analysis of studies in stable coronary disease found that a negative FFRCT (above 0.80) was linked to a lower risk of unfavorable outcomes, and the lower the number went, the higher the risk climbed.

In a long-term study of 2,566 people with coronary artery disease, CT-FFR was a strong, independent predictor of long-term events. In another 206-person study, a CT-FFR value of 0.80 or less predicted long-term outcomes (mostly planned and unplanned revascularization) better than the appearance of significant stenosis on the CT scan.

Heart Transplant Vasculopathy

For people who have had a heart transplant, the left circumflex and the other coronary arteries can develop a slow, diffuse form of disease called cardiac allograft vasculopathy. In a study of transplant recipients, distal FFRCT in the LCX and other vessels gradually decreased over time even without focal narrowings, and these changes tracked with worsening vessel disease.

What this means for you: if you have had a heart transplant, serial FFRCT values in the LCX and other arteries can flag diffuse disease that a snapshot stenosis read might miss.

Reference Ranges and Cutpoints

These ranges come from research using invasive fractional flow reserve as the reference standard. The most commonly used threshold is 0.80, but the same value can carry different certainty depending on the broader picture. Your scan center may report values from any of several commercial or on-site algorithms, so compare your results within the same system over time.

RangeInterpretationWhat It Suggests
Above 0.80Normal or non-flow-limitingVery low rate of heart events over the next 1 to 5 years
0.76 to 0.80Gray zoneDecision depends on symptoms, plaque burden, and other tests
0.75 or belowFunctionally significant ischemiaStrong case for further investigation and possible revascularization

Risk does not flip at exactly 0.80. Each 0.05 to 0.10 drop in FFRCT has been linked to a step-up in major adverse event risk. A value of 0.79 and a value of 0.65 are not the same kind of "abnormal," even though both technically fall below the cutoff.

Where the Measurement Is Taken Matters

FFRCT naturally falls from the start of an artery to its end, even in completely normal vessels. The very distal LCX is a small caliber vessel, and software can return values at or below 0.80 there even when no real narrowing exists.

In a study of patients undergoing FFRCT analysis, measuring FFRCT only at the very distal vessel overcalled ischemia: many "positive" distal FFRCT values flipped to negative when the measurement was repeated about 10.5 mm past the actual narrowing. In a study of asymptomatic marathon runners with no stenosis, 8% had distal LCX FFRCT values of 0.80 or lower, despite having no detectable disease.

This is why context matters. A low minimum FFRCT in the distal LCX without a corresponding narrowing on the CT image is not the same as a low value caused by a real lesion. Read the value alongside the actual plaque anatomy.

Tracking Your Trend

FFRCT is not a number you check every few months. A coronary CT angiogram involves contrast dye and radiation, so retesting decisions weigh that exposure against the value of new information. For most people, a baseline scan with FFRCT gives a snapshot of your coronary anatomy and physiology, and follow-up imaging is driven by symptoms, risk changes, or planned reassessments.

That said, in specific situations, repeating the test does add information. In heart transplant recipients, serial FFRCT can track diffuse vessel disease that focal stenosis reads miss. In people with non-obstructive disease, repeat scans over years have shown that worsening FFRCT plus plaque progression predicts higher cardiovascular event rates than either change alone.

When Results Can Be Misleading

A few situations can shift the number on the report without reflecting your true coronary physiology:

  • Distal small-vessel measurements: a low minimum FFRCT in the very distal LCX without a matching narrowing on the scan often overestimates ischemia and may not represent real disease.
  • Heavy coronary calcification: very high calcium burden can degrade CT image quality and reduce algorithm accuracy, though CT-FFR still outperforms CCTA alone in this setting.
  • Poor image quality: motion artifact, irregular heart rhythms, or suboptimal contrast timing can produce calculations the algorithm flags as low confidence.
  • Algorithm differences: different vendors (HeartFlow, AccuFFRct, on-site machine learning tools) can produce slightly different numbers from the same scan.

What an Abnormal Result Should Prompt

If your minimum FFRCT in the LCX comes back below 0.80, the next step depends on the full picture, not the single number. Look at where in the artery the low value sits, how it lines up with visible narrowings, the size of the heart territory the LCX supplies, and your symptoms.

A clearly low value (below about 0.70) with a matching narrowing on the CT is a strong reason to talk with a cardiologist about invasive coronary angiography and possible revascularization. A gray-zone value (0.76 to 0.80) with no symptoms and modest plaque often warrants intensified medical therapy (statin optimization, blood pressure control, lifestyle change) and a plan for follow-up rather than an immediate trip to the catheterization lab. A clearly normal value above 0.80 makes flow-limiting disease in that artery very unlikely, and short-term event rates are low.

What This Test Cannot Tell You

FFRCT in the LCX reflects flow physiology in one specific artery at the moment your scan was taken. It does not measure plaque inflammation, microvascular dysfunction in the smaller arteries beyond the LCX, or how your arteries will respond to stress over time. It is one slice of your cardiovascular picture, best read alongside lipid markers, inflammation markers, blood pressure, and the rest of your CT angiography findings.

What Moves This Biomarker

Evidence-backed interventions that affect your Minimum FFRCT - LCX level

↑ Increase
Revascularization (percutaneous coronary intervention or bypass surgery) for the identified narrowing
If a minimum FFRCT below 0.80 reflects a real, focal narrowing in the LCX, opening or bypassing that narrowing restores flow through the artery and would be expected to raise the value back toward normal. In real-world registries of patients with obstructive disease on CT, FFRCT-guided revascularization was linked to lower rates of major adverse cardiac events after the procedure compared with cases managed without the functional information.
MedicationStrong Evidence

Frequently Asked Questions

References

18 studies
  1. Gassenmaier S, Tsiflikas I, Greulich S, Kuebler J, Hagen F, Nikolaou K, Niess a, Burgstahler C, Krumm PEuropean Radiology2021
  2. Sharma SP, Sanz J, Hirsch a, Patel R, Constantinescu a, Barghash M, Mancini DM, Brugts J, Caliskan KC, Taverne Y, Manintveld O, Budde RPEuropean Radiology2024
  3. Budde R, Nous F, Roest S, Constantinescu a, Nieman K, Brugts J, Koweek L, Hirsch a, Leipsic J, Manintveld OEuropean Radiology2021
  4. Norgaard B, Leipsic J, Gaur S, Seneviratne S, Ko B, Ito H, Jensen J, Mauri L, De Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis a, Park SJ, Christiansen EH, Kaltoft a, Lassen J, Botker H, Achenbach SJournal of the American College of Cardiology2014